Breaking News Instant updates and real-time market news.

2020-12-28 06:02:21 NKLA Nikola $13.82 / -1.22 (-8.11%) , GM General Motors $41.54 / -0.895 (-2.11%) … 06:02 12/28/20 12/28 06:02 12/28/20 06:02	JPMorgan cuts Nikola target but sees 'generally positive' news flow in 2021 JPMorgan analyst Paul Coster lowered the firm's price target on Nikola (NKLA) to $35 from $40 and keeps an Overweight rating on the shares. The reduced year-end 2021 price target reflects the execution risk associated with a "tarnished brand," Coster tells investors in a research note. The analyst, however, expects the Nikola news flow "to be less drama-filled and to turn generally positive" in 2021. The shares have traded down 50% in the last month on news that the General Motors (GM) and Republic Services (RSG) partnerships have been abandoned, Coster says. He believes Nikola was "prudent" to exit these arrangements, preserving cash for execution of the Class 8 truck initiative. GM could still play an important role as a second-source supplier of fuel cells, notes Coster. The analyst expects Nikola to post a video of a functioning Tre in January and he looks for a "steady flow" of updates for the truck in 2021. NKLA Nikola $13.82 / -1.22 (-8.11%) GM General Motors $41.54 / -0.895 (-2.11%) RSG Republic Services $95.59 / +0.445 (+0.47%)	11 Jan
NKLA GM RSG NKLA Nikola $13.82 / -1.22 (-8.11%) 12/24/20 Loop Capital Nikola faces 'another setback in a series of setbacks,' says Loop Capital 12/16/20 Fly Intel: Top five analyst initiations 12/16/20 Colliers Nikola initiated with a Neutral at Colliers 12/15/20 Evercore ISI starts Nikola at In Line, says stock 'far from clean story' GM General Motors $41.54 / -0.895 (-2.11%) 12/23/20 Morgan Stanley Apple's potential EV entry represents 'new Tesla bear case,' says Morgan Stanley 12/22/20 Citi Citi 'very skeptical' of Apple car, says Tesla most direct competitor 12/21/20 Benchmark General Motors price target raised to $51 from $47 at Benchmark 12/17/20 Barclays General Motors price target raised to $49 from $45 at Barclays RSG Republic Services $95.59 / +0.445 (+0.47%) 11/18/20 Argus Republic Services price target raised to $110 from $102 at Argus 10/27/20 BofA Waste Management downgraded to Underperform on rotation risk at BofA 10/19/20 Jefferies Republic Services upgraded to Buy from Hold at Jefferies

2020-12-28 06:02:21

NKLA

Nikola

$13.82 / -1.22 (-8.11%)

, GM

General Motors

$41.54 / -0.895 (-2.11%)

… 06:02

12/28/20

12/28

06:02

12/28/20

06:02

JPMorgan cuts Nikola target but sees 'generally positive' news flow in 2021

JPMorgan analyst Paul Coster lowered the firm's price target on Nikola (NKLA) to $35 from $40 and keeps an Overweight rating on the shares. The reduced year-end 2021 price target reflects the execution risk associated with a "tarnished brand," Coster tells investors in a research note. The analyst, however, expects the Nikola news flow "to be less drama-filled and to turn generally positive" in 2021. The shares have traded down 50% in the last month on news that the General Motors (GM) and Republic Services (RSG) partnerships have been abandoned, Coster says. He believes Nikola was "prudent" to exit these arrangements, preserving cash for execution of the Class 8 truck initiative. GM could still play an important role as a second-source supplier of fuel cells, notes Coster. The analyst expects Nikola to post a video of a functioning Tre in January and he looks for a "steady flow" of updates for the truck in 2021.

NKLA

Nikola

$13.82 / -1.22 (-8.11%)

General Motors

$41.54 / -0.895 (-2.11%)

RSG

Republic Services

$95.59 / +0.445 (+0.47%)

11
Jan

NKLA
GM
RSG

NKLA Nikola

$13.82 / -1.22 (-8.11%)

12/24/20 Loop Capital: Nikola faces 'another setback in a series of setbacks,' says Loop Capital

12/16/20: Fly Intel: Top five analyst initiations

12/16/20 Colliers: Nikola initiated with a Neutral at Colliers

12/15/20: Evercore ISI starts Nikola at In Line, says stock 'far from clean story'

GM General Motors

$41.54 / -0.895 (-2.11%)

12/23/20 Morgan Stanley: Apple's potential EV entry represents 'new Tesla bear case,' says Morgan Stanley

12/22/20 Citi: Citi 'very skeptical' of Apple car, says Tesla most direct competitor

12/21/20 Benchmark: General Motors price target raised to $51 from $47 at Benchmark

12/17/20 Barclays: General Motors price target raised to $49 from $45 at Barclays

RSG Republic Services

$95.59 / +0.445 (+0.47%)

11/18/20 Argus: Republic Services price target raised to $110 from $102 at Argus

10/27/20 BofA: Waste Management downgraded to Underperform on rotation risk at BofA

10/19/20 Jefferies: Republic Services upgraded to Buy from Hold at Jefferies

TODAY'S FREE FLY STORIES

Syndicate	nLight 2.206M share Spot Secondary priced at $34.00 » 07:42 03/04/21 03/04 07:42 03/04/21 07:42 LASR nLight $36.79 / -0.93 (-2.47%) The deal range was… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Earnings Syndicate On The Fly LASR nLight $36.79 / -0.93 (-2.47%) 02/18/21 DA Davidson nLight price target raised to $48 from $30 at DA Davidson 02/18/21 Craig-Hallum nLight price target raised to $48 from $32 at Craig-Hallum 02/18/21 Canaccord nLight price target raised to $53 from $27 at Canaccord 01/21/21 Berenberg nLight assumed with a Hold at Berenberg LASR nLight $36.79 / -0.93 (-2.47%) 02/17/21 nLight sees Q1 revenue $56M-$62M, consensus $56.13M 02/17/21 nLight reports Q4 adjusted EPS 12c, consensus 6c 11/05/20 nLight sees Q4 revenue $59M-$65M, consensus $56.8M 11/05/20 nLight reports Q3 EPS 12c, consensus 1c 04 Mar LASR nLight $36.79 / -0.93 (-2.47%) 03/03/21 Fly Intel: After-Hours Movers 11/05/20 Fly Intel: After-Hours Movers
Downgrade	WSFS Financial downgraded to Neutral from Outperform at Boenning & Scattergood » 07:41 03/04/21 03/04 07:41 03/04/21 07:41 WSFS WSFS Financial $51.90 / +0.68 (+1.33%) Boenning &… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly WSFS WSFS Financial $51.90 / +0.68 (+1.33%) 03/01/21 WSFS Financial to replace Cleveland-Cliffs in S&P 600 at open on 3/1 02/23/21 WSFS Financial to replace Cleveland-Cliffs in S&P 600 at open on 3/1 WSFS WSFS Financial $51.90 / +0.68 (+1.33%) 03/01/21 Piper Sandler WSFS Financial downgraded to Neutral from Overweight at Piper Sandler 02/25/21 Keefe Bruyette WSFS Financial downgraded to Market Perform from Outperform at Keefe Bruyette 04/01/20 Keefe Bruyette WSFS Financial upgraded to Outperform from Market Perform at Keefe Bruyette WSFS WSFS Financial $51.90 / +0.68 (+1.33%) 01/25/21 WSFS Financial reports Q4 EPS $1.20, consensus 91c 10/22/20 WSFS Financial reports Q3 EPS $1.01, consensus 72c WSFS WSFS Financial $51.90 / +0.68 (+1.33%) 01/25/21 Fly Intel: After-Hours Movers
Hot Stocks	Skylight Health to acquire three U.S. primary care practices » 07:41 03/04/21 03/04 07:41 03/04/21 07:41 SHGFF Skylight Health $0.00 / + (+0.00%) Skylight Health Group is… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research SHGFF Skylight Health $0.00 / + (+0.00%) 02/26/21 Skylight Health appoints Andrew Elinesky as CFO 02/24/21 Skylight Health to host KOL event on U.S. healthcare market 02/17/21 Skylight Health appoints Jerry Oliphant as COO, Georges Feghali as CMO 02/09/21 Skylight Health appoints Paul Kulas as SVP, operations SHGFF Skylight Health $0.00 / + (+0.00%) 02/24/21 Raymond James Skylight Health initiated with an Outperform at Raymond James
Hot Stocks	Dyne Therapeutics expects cash to fund requirements into 2H24 » 07:40 03/04/21 03/04 07:40 03/04/21 07:40 DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) In January 2021, Dyne… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 07:30 Today Dyne Therapeutics appoints Wildon Farwell as CMO 02/08/21 Dyne Therapeutics appoints Ashish Dugar as SVP, global head of medical affairs 01/10/21 Dyne Therapeutics announced new preclinical data from DM1 program 09/28/20 Citadel Advisors takes 6.5% passive stake in Dyne Therapeutics DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 02/09/21 Dyne Therapeutics initiated with a Buy at JonesTrading 01/07/21 Piper Sandler Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper 10/12/20 Jefferies Dyne Therapeutics initiated with a Buy at Jefferies 10/12/20 JPMorgan Dyne Therapeutics initiated with an Overweight at JPMorgan DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 07:39 Today Dyne Therapeutics reports Q4 EPS (64c), consensus (37c) 11/05/20 Dyne Therapeutics reports Q3 EPS ($2.01), consensus (87c) 21 Jan 17 Sep DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 01/21/21 Fly Intel: Wall Street's top stories for Thursday 01/21/21 Fly Intel: Wall Street's top stories at midday 09/28/20 Fly Intel: After-Hours Movers 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever
Earnings	Dyne Therapeutics reports Q4 EPS (64c), consensus (37c) » 07:39 03/04/21 03/04 07:39 03/04/21 07:39 DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) "2020 was a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 07:30 Today Dyne Therapeutics appoints Wildon Farwell as CMO 02/08/21 Dyne Therapeutics appoints Ashish Dugar as SVP, global head of medical affairs 01/10/21 Dyne Therapeutics announced new preclinical data from DM1 program 09/28/20 Citadel Advisors takes 6.5% passive stake in Dyne Therapeutics DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 02/09/21 Dyne Therapeutics initiated with a Buy at JonesTrading 01/07/21 Piper Sandler Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper 10/12/20 Jefferies Dyne Therapeutics initiated with a Buy at Jefferies 10/12/20 JPMorgan Dyne Therapeutics initiated with an Overweight at JPMorgan DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 11/05/20 Dyne Therapeutics reports Q3 EPS ($2.01), consensus (87c) 21 Jan 17 Sep DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 01/21/21 Fly Intel: Wall Street's top stories for Thursday 01/21/21 Fly Intel: Wall Street's top stories at midday 09/28/20 Fly Intel: After-Hours Movers 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever

Hot Stocks	Arbutus Biopharma sees cash runway into 3Q22 » 07:38 03/04/21 03/04 07:38 03/04/21 07:38 ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) Arbutus had cash, cash… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 02/26/21 Assembly Biosciences, Arbutus initiate Phase 2 trial of combination therapy 01/25/21 Arbutus Biopharma sees cash runway into mid-2022 01/25/21 Arbutus Biopharma announces 2021 corporate objectives 12/10/20 Arbutus Biopharma announces additional HBsAg decline data with AB-729 ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 12/17/20 H.C. Wainwright Arbutus Biopharma initiated with a Buy at H.C. Wainwright 09/15/20 Chardan Arbutus HBV data 'could represent a turning point,' says Chardan 07/27/20 B. Riley FBR Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR 07/24/20 Baird Arbutus Biopharma upside priced in, Baird downgrades to Neutral ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 07:38 Today Arbutus Biopharma reports 2020 EPS ($1.00), consensus (98c) 11/05/20 Arbutus Biopharma reports Q3 EPS (27c), consensus (22c) 08:45 Today Arbutus Biopharma - ABUS ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 12/15/20 Arbutus Biopharma call buyer realizes 80% same-day gains
Initiation	Histogen initiated with a Buy at Canaccord » 07:38 03/04/21 03/04 07:38 03/04/21 07:38 HSTO Histogen $1.15 / -0.035 (-2.95%) Canaccord Genuity analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Syndicate Options HSTO Histogen $1.15 / -0.035 (-2.95%) 02/16/21 Histogen announces Week 26 HST-001 study results 01/19/21 Histogen reports clinical hold on Phase 1/2 Trial of HST-003 for knee cartilage 12/17/20 Histogen files IND application for HST-003 12/01/20 Histogen announces preliminary week 18 HST-001 study results 31 Dec HSTO Histogen $1.15 / -0.035 (-2.95%) 01/19/21 Nine new option listings and thirteen option delistings on January 19th
Earnings	Arbutus Biopharma reports 2020 EPS ($1.00), consensus (98c) » 07:38 03/04/21 03/04 07:38 03/04/21 07:38 ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) Reports 2020 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 02/26/21 Assembly Biosciences, Arbutus initiate Phase 2 trial of combination therapy 01/25/21 Arbutus Biopharma sees cash runway into mid-2022 01/25/21 Arbutus Biopharma announces 2021 corporate objectives 12/10/20 Arbutus Biopharma announces additional HBsAg decline data with AB-729 ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 12/17/20 H.C. Wainwright Arbutus Biopharma initiated with a Buy at H.C. Wainwright 09/15/20 Chardan Arbutus HBV data 'could represent a turning point,' says Chardan 07/27/20 B. Riley FBR Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR 07/24/20 Baird Arbutus Biopharma upside priced in, Baird downgrades to Neutral ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 11/05/20 Arbutus Biopharma reports Q3 EPS (27c), consensus (22c) 08:45 Today Arbutus Biopharma - ABUS ABUS Arbutus Biopharma $3.64 / -0.19 (-4.97%) 12/15/20 Arbutus Biopharma call buyer realizes 80% same-day gains
Hot Stocks	Dicerna, Roche begin combo trial of GalXC for chronic HBV treatment » 07:37 03/04/21 03/04 07:37 03/04/21 07:37 DRNA Dicerna $29.00 / -0.52 (-1.76%) , RHHBY Roche $0.00 / + (+0.00%) Dicerna Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events DRNA RHHBY DRNA Dicerna $29.00 / -0.52 (-1.76%) 02/11/21 Dicerna initiates dosing in clinical trial of nedosiran for PH3 01/05/21 Dicerna announces first Novo Nordisk nominated candidate under agreement 01/04/21 Dicerna reports enrollment completion of PHYOX2 nedosiran trial 11/16/20 Dicerna gets $10M milestone from Lilly pact, Lilly initiates LY3561774 trial RHHBY Roche $0.00 / + (+0.00%) 03/03/21 Adaptive says Genentech suspends development of shared antigen target candidate 02/26/21 Regeneron announces CHMP recommendation for COVID-19 antibody cocktail 02/24/21 Prothena announces presentation of new preclinical PRX005 data 02/19/21 Atea Pharmaceuticals announces Chugai in-license of AT-527 from Roche DRNA RHHBY DRNA Dicerna $29.00 / -0.52 (-1.76%) 03/02/21 H.C. Wainwright Dicerna price target raised to $40 from $35 at H.C. Wainwright 03/02/21 Chardan Dicerna price target raised to $34 from $25 at Chardan 03/01/21 B. Riley Securities Dicerna price target raised to $40 from $37 at B. Riley Securities 01/11/21 B. Riley Securities Dicerna price target raised to $37 from $30 at B. Riley Securities RHHBY Roche $0.00 / + (+0.00%) 03/03/21 Goldman Sachs Adaptive Biotechnologies downgraded to Neutral from Buy at Goldman Sachs 02/25/21 Berenberg Roche price target lowered to CHF 320 from CHF 325 at Berenberg 02/24/21 Morgan Stanley Roche price target lowered to CHF 345 from CHF 365 at Morgan Stanley 02/23/21 BofA BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list DRNA RHHBY DRNA Dicerna $29.00 / -0.52 (-1.76%) 02/25/21 Dicerna reports FY20 EPS ($1.52), consensus ($1.05) 11/05/20 Dicerna reports Q3 EPS (29c), consensus (20c) RHHBY Roche $0.00 / + (+0.00%) 02/04/21 Roche reports 2020 core EPS CHF 19.16 vs. CHF 20.16 last year 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year RHHBY RHHBY Roche $0.00 / + (+0.00%) 02/11/21 Roche arthritis drug reduced Covid deaths in study, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports DRNA RHHBY DRNA Dicerna $29.00 / -0.52 (-1.76%) 02/25/21 Fly Intel: After-Hours Movers RHHBY Roche $0.00 / + (+0.00%) 12/26/20 Week in review: How Trump's policies moved stocks 11/30/20 Fly Intel: Wall Street's top stories for Monday 11/30/20 Fly Intel: Wall Street's top stories at midday 11/21/20 Week in review: How Trump's policies moved stocks 03/25/21 Roche - RHHBY
Upgrade	Agricultural Bank of China upgraded to Buy from Neutral at Goldman Sachs » 07:37 03/04/21 03/04 07:37 03/04/21 07:37 ACGBY Agricultural Bank of China $0.00 / + (+0.00%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research ACGBY Agricultural Bank of China $0.00 / + (+0.00%) 04/03/20 Jefferies Agricultural Bank of China initiated with a Buy at Jefferies

Hot Stocks	Verrica Pharmaceuticals expects cash to support operations at least into 1Q22 » 07:36 03/04/21 03/04 07:36 03/04/21 07:36 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) As of December 31, 2020,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 07:35 Today Verrica says Torii exercises option to acquire license for VP-102 07:34 Today Verrica Pharmaceuticals resubmits NDA for VP-102 02/17/21 Verrica announces acceptance of resubmitted NDA filing for VP-102 01/19/21 Verrica Pharmaceuticals presents data from clinical studies of VP-102 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 12/24/20 Cowen Verrica approval for molluscum likely in Q3 of 2021, says Cowen 12/24/20 H.C. Wainwright Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright 07/15/20 BofA Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA 06/30/20 H.C. Wainwright Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 07:33 Today Verrica Pharmaceuticals reporrts Q4 EPS (52c), consensus (42c) 11/09/20 Verrica Pharmaceuticals reports Q3 EPS (42c), consensus (43c) 06/23/21 PDFUA Date for VP-102 Resubmission
Upgrade	Canaccord upgrades Okta to Buy on recent selloff, accretive acquisition » 07:36 03/04/21 03/04 07:36 03/04/21 07:36 OKTA Okta $242.42 / -16.595 (-6.41%) Canaccord analyst T.… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options OKTA Okta $242.42 / -16.595 (-6.41%) 03/03/21 Okta drops 13% to $210.50 after Q1, FY22 profit view miss estimates 03/03/21 Okta to acquire Auth0 in deal valued at roughly $6.5B 12/02/20 Okta jumps 6.8% to $246 after Q3 results, FY21 guidance, AWS availability 12/02/20 Okta announces availability of Identity Cloud in AWS Marketplace OKTA Okta $242.42 / -16.595 (-6.41%) 06:53 Today Deutsche Bank Okta price target lowered to $270 from $313 at Deutsche Bank 06:45 Today Mizuho Okta price target lowered to $255 from $305 at Mizuho 06:37 Today Baird Okta price target lowered to $240 from $275 at Baird 06:06 Today Piper Sandler Okta price target lowered to $235 from $250 at Piper Sandler OKTA Okta $242.42 / -16.595 (-6.41%) 03/03/21 Okta sees FY22 adjusted EPS (49c)-(44c), consensus 1c 03/03/21 Okta sees Q1 adjusted EPS (21c)-(20c), consensus (7c) 03/03/21 Okta reports Q4 adjusted EPS 6c, consensus (1c) 03/03/21 Notable companies reporting after market close OKTA Okta $242.42 / -16.595 (-6.41%) 03/03/21 Fly Intel: After-Hours Movers 12/21/20 Analysts move to sidelines on SolarWinds following cyberattack 12/09/20 JPMorgan downgrades Zoom, upgrades Autodesk in software ratings shakeup 12/02/20 Fly Intel: After-Hours Movers OKTA Okta $242.42 / -16.595 (-6.41%) 12/02/20 Okta options imply 9.8% move in share price post-earnings
Hot Stocks	Verrica says Torii exercises option to acquire license for VP-102 » 07:35 03/04/21 03/04 07:35 03/04/21 07:35 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) On March 2, Torii… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 07:34 Today Verrica Pharmaceuticals resubmits NDA for VP-102 02/17/21 Verrica announces acceptance of resubmitted NDA filing for VP-102 01/19/21 Verrica Pharmaceuticals presents data from clinical studies of VP-102 12/23/20 Verrica Pharmaceuticals resubmits VP-102 NDA VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 12/24/20 Cowen Verrica approval for molluscum likely in Q3 of 2021, says Cowen 12/24/20 H.C. Wainwright Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright 07/15/20 BofA Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA 06/30/20 H.C. Wainwright Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 07:33 Today Verrica Pharmaceuticals reporrts Q4 EPS (52c), consensus (42c) 11/09/20 Verrica Pharmaceuticals reports Q3 EPS (42c), consensus (43c) 06/23/21 PDFUA Date for VP-102 Resubmission
Upgrade	Postal Savings Bank of China upgraded to Conviction Buy at Goldman Sachs » 07:34 03/04/21 03/04 07:34 03/04/21 07:34 PSTVY Postal Savings Bank of China $0.00 / + (+0.00%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Hot Stocks	Verrica Pharmaceuticals resubmits NDA for VP-102 » 07:34 03/04/21 03/04 07:34 03/04/21 07:34 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) The Company recently… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 02/17/21 Verrica announces acceptance of resubmitted NDA filing for VP-102 01/19/21 Verrica Pharmaceuticals presents data from clinical studies of VP-102 12/23/20 Verrica Pharmaceuticals resubmits VP-102 NDA 11/17/20 Verrica Pharmaceuticals expects to resubmit VP-102 NDA in 1Q21 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 12/24/20 Cowen Verrica approval for molluscum likely in Q3 of 2021, says Cowen 12/24/20 H.C. Wainwright Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright 07/15/20 BofA Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA 06/30/20 H.C. Wainwright Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 07:33 Today Verrica Pharmaceuticals reporrts Q4 EPS (52c), consensus (42c) 11/09/20 Verrica Pharmaceuticals reports Q3 EPS (42c), consensus (43c) 06/23/21 PDFUA Date for VP-102 Resubmission

Earnings	Syros Pharmaceuticals reports Q4 EPS (62c), consensus (50c) » 07:33 03/04/21 03/04 07:33 03/04/21 07:33 SYRS Syros Pharmaceuticals $8.33 / -0.87 (-9.46%) Reports Q4 revenue $5.7M,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events SYRS Syros Pharmaceuticals $8.33 / -0.87 (-9.46%) 12/06/20 Syros acquires clinical-stage drug candidate for Acute Promyelocytic Leukemia 12/06/20 Syros Pharmaceuticals presents new data from Phase 2 trial of SY-1425 11/04/20 Syros to present new data from Phase 2 SY-1425 trial at ASH meeting 10/25/20 Syros presents initial data from Phase 1 trial of SY-5609 SYRS Syros Pharmaceuticals $8.33 / -0.87 (-9.46%) 11/10/20 Brookline Syros Pharmaceuticals initiated with a Buy at Brookline 11/05/20 Roth Capital Syros' SY-1425+Aza could be competitive in multiple settings, says Roth Capital 11/04/20 Fly Intel: Top five analyst upgrades 11/04/20 H.C. Wainwright Syros Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright SYRS Syros Pharmaceuticals $8.33 / -0.87 (-9.46%) 11/05/20 Syros Pharmaceuticals reports Q3 EPS (43c), consensus (38c) 20 Jan SYRS Syros Pharmaceuticals $8.33 / -0.87 (-9.46%) 01/19/21 Fly Intel: After-Hours Movers 01/07/21 Fly Intel: After-Hours Movers 08:30 Today Syros Pharmaceuticals - SYRS
General news	Challenger Job-Cut Report Level data reported » 07:33 03/04/21 03/04 07:33 03/04/21 07:33 February Challenger… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Earnings	Verrica Pharmaceuticals reporrts Q4 EPS (52c), consensus (42c) » 07:33 03/04/21 03/04 07:33 03/04/21 07:33 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) "Over the past year,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 02/17/21 Verrica announces acceptance of resubmitted NDA filing for VP-102 01/19/21 Verrica Pharmaceuticals presents data from clinical studies of VP-102 12/23/20 Verrica Pharmaceuticals resubmits VP-102 NDA 11/17/20 Verrica Pharmaceuticals expects to resubmit VP-102 NDA in 1Q21 VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 12/24/20 Cowen Verrica approval for molluscum likely in Q3 of 2021, says Cowen 12/24/20 H.C. Wainwright Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright 07/15/20 BofA Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA 06/30/20 H.C. Wainwright Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright VRCA Verrica Pharmaceuticals $15.18 / +0.97 (+6.83%) 11/09/20 Verrica Pharmaceuticals reports Q3 EPS (42c), consensus (43c) 06/23/21 PDFUA Date for VP-102 Resubmission
Downgrade	Yext downgraded to Market Perform on growth headwinds at William Blair » 07:32 03/04/21 03/04 07:32 03/04/21 07:32 YEXT Yext $16.55 / -1.16 (-6.55%) William Blair analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events YEXT Yext $16.55 / -1.16 (-6.55%) 03/03/21 Yext drops 13% to $14.29 after Q4 results, FY22 guidance 02/23/21 Yext COO sells 80K shares of common stock 02/08/21 Yext names David Rudnitsky as President and Chief Revenue Officer 02/03/21 Yext and Carahsoft partner to develop search technology for public sector YEXT Yext $16.55 / -1.16 (-6.55%) 05:36 Today William Blair Yext downgraded to Market Perform from Outperform at William Blair 12/04/20 DA Davidson Yext price target lowered to $20.50 from $22 at DA Davidson 12/04/20 Truist Yext growth should pick up next year, says Truist 07/09/20 Needham Yext price target raised to $21 from $19 at Needham YEXT Yext $16.55 / -1.16 (-6.55%) 03/03/21 Yext sees Q1 non-GAAP EPS (7c)-(5c), consensus (6c) 03/03/21 Yext sees FY22 non-GAAP EPS (22c)-(17c) , consensus (27c) 03/03/21 Yext reports Q4 non-GAAP EPS 0c, consensus (8c) 12/03/20 Yext sees Q4 adjusted EPS (10c)-(8c), consensus (8c) YEXT Yext $16.55 / -1.16 (-6.55%) 03/03/21 Fly Intel: After-Hours Movers 12/04/20 Fly Intel: Wall Street's top stories for Friday 12/04/20 Fly Intel: Wall Street's top stories at midday 12/03/20 Fly Intel: After-Hours Movers 03/23/21 Yext
Hot Stocks	DraftKings becomes 'Official Sportsbook, Daily Fantasy Partner' of UFC » 07:32 03/04/21 03/04 07:32 03/04/21 07:32 DKNG DraftKings $65.75 / -2.785 (-4.06%) DraftKings will become… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options DKNG DraftKings $65.75 / -2.785 (-4.06%) 03/03/21 Dish, DraftKings announce strategic agreement 02/26/21 DraftKings MUPs for B2C segment up 44% vs. 4Q19 02/25/21 Bill introduced in Florida Senate to authorize sports wagering 02/25/21 Nevada reports January statewide gaming win down 26.6% to $761.85M DKNG DraftKings $65.75 / -2.785 (-4.06%) 03/01/21 Craig-Hallum DraftKings price target raised to $70 from $65 at Craig-Hallum 03/01/21 Canaccord DraftKings price target raised to $80 from $65 at Canaccord 03/01/21 Northland DraftKings price target raised to $70 from $55 at Northland 03/01/21 Benchmark DraftKings price target raised to $69 from $66 at Benchmark DKNG DraftKings $65.75 / -2.785 (-4.06%) 02/26/21 DraftKings raises 2021 revenue view to $900M-$1B from $750M-$850M 02/26/21 DraftKings reports Q4 revenue $322M, consensus $232.6M 02/25/21 Notable companies reporting before tomorrow's open 02/25/21 Notable companies reporting before tomorrow's open 07 Oct 19 Jun DKNG DraftKings $65.75 / -2.785 (-4.06%) 03/02/21 Hedgeye adds DraftKings as a Best Idea Short 03/02/21 Connecticut, Mohegan Tribe reach deal on sports betting, The Day reports 02/12/21 Nevada to roll back capacity restrictions on casinos, Reno Gazette Journal says 02/09/21 TX Lt. Gov. sees no support for legalized sports betting, Houston Chronicle says DKNG DraftKings $65.75 / -2.785 (-4.06%) 03/01/21 Fly Intel: Wall Street's top stories for Monday 02/26/21 Fly Intel: Wall Street's top stories for Friday 02/26/21 Bet On It: Florida and Texas trying to get in on the action 02/26/21 Fly Intel: Wall Street's top stories at midday 03/09/21 DraftKings Inc DKNG DraftKings $65.75 / -2.785 (-4.06%) 02/02/21 DraftKings call volume above normal and directionally bullish 01/27/21 DraftKings call volume above normal and directionally bullish 01/26/21 DraftKings call volume above normal and directionally bullish 01/12/21 DraftKings call volume above normal and directionally bullish

Hot Stocks	CureVac and Novartis in initial pact on Covid vaccine candidate » 07:31 03/04/21 03/04 07:31 03/04/21 07:31 CVAC CureVac $83.44 / -9.76 (-10.47%) , NVS Novartis $84.16 / -0.635 (-0.75%) CureVac (CVAC) and… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options CVAC NVS CVAC CureVac $83.44 / -9.76 (-10.47%) 02/05/21 CureVac enters pact with UK Government to develop SARS-CoV-2 variant vaccine 02/04/21 CureVac expands CV8102 cancer program to advanced melanoma 02/03/21 CureVac, GSK in pact to jointly develop mRNA vaccines for COVID-19 01/07/21 Bayer signs collaboration, services agreement with CureVac for COVID-19 vaccine NVS Novartis $84.16 / -0.635 (-0.75%) 03/02/21 Novartis shareholders approve 1.7% increase in dividend to CHF 3.00 per share 03/01/21 Homology Medicines regains worldwide rights to ophthalmology program 02/17/21 Novartis announces SCD grant agreement with Bill & Melinda Gates Foundation 02/16/21 Novartis reports Entresto granted expanded indication in chronic heart failure CVAC NVS CVAC CureVac $83.44 / -9.76 (-10.47%) 01/07/21 Morgan Stanley CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley 12/10/20 Credit Suisse CureVac downgraded to Underperform on rising valuation at Credit Suisse 12/10/20 Credit Suisse CureVac downgraded to Underperform from Neutral at Credit Suisse 11/02/20 Piper Sandler CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper NVS Novartis $84.16 / -0.635 (-0.75%) 03/01/21 Oppenheimer Homology Medicines loses potential source of upside, says Oppenheimer 02/02/21 Morgan Stanley Novartis price target lowered to CHF 102 from CHF 104 at Morgan Stanley 02/01/21 Truist iRhythm price target lowered to $220 from $265 at Truist 02/01/21 Cowen Novartis downgraded to Market Perform after 'tepid' guidance at Cowen NVS NVS Novartis $84.16 / -0.635 (-0.75%) 01/26/21 Novartis sees 2021 core operating income to grow mid single digit 01/26/21 Novartis reports Q4 core EPS $1.34, consensus $1.36 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook 28 Jan 14 Aug CVAC NVS CVAC CureVac $83.44 / -9.76 (-10.47%) 01/06/21 CureVac, Bayer reach alliance deal over COVID-19 vaccine, Reuters says 09/04/20 Germany awards grant to CureVac to accelerate vaccine development, BI reports NVS Novartis $84.16 / -0.635 (-0.75%) 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports CVAC NVS CVAC CureVac $83.44 / -9.76 (-10.47%) 01/25/21 Fly Intel: After-Hours Movers 01/07/21 Fly Intel: Pre-market Movers 11/10/20 Fly Intel: Pre-market Movers 11/02/20 Fly Intel: Pre-market Movers NVS Novartis $84.16 / -0.635 (-0.75%) 02/11/21 Fly Intel: Wall Street's top stories for Thursday 02/11/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: Pre-market Movers 12/26/20 Week in review: How Trump's policies moved stocks CVAC CVAC CureVac $83.44 / -9.76 (-10.47%) 12/03/20 Largest borrow rate increases among liquid names 09/29/20 Largest borrow rate increases among liquid names 09/15/20 Largest borrow rate increases among liquid names 09/11/20 Largest borrow rate increases among liquid names
Hot Stocks	Dyne Therapeutics appoints Wildon Farwell as CMO » 07:30 03/04/21 03/04 07:30 03/04/21 07:30 DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) , BIIB Biogen $266.84 / -3.2 (-1.19%) Dyne Therapeutics (DYN)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options DYN BIIB DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 02/08/21 Dyne Therapeutics appoints Ashish Dugar as SVP, global head of medical affairs 01/10/21 Dyne Therapeutics announced new preclinical data from DM1 program 09/28/20 Citadel Advisors takes 6.5% passive stake in Dyne Therapeutics BIIB Biogen $266.84 / -3.2 (-1.19%) 02/03/21 Biogen sees FY21 adjusted R&D expense $2.35B-$2.45B 02/03/21 Biogen CEO sees 'a financial reset in 2021' 02/01/21 Biogen announces FDA approval of PLEGRIDY intramuscular administration 01/29/21 Biogen, Eisai announce 3-month extension of review period for aducanumab BLA DYN BIIB DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 02/09/21 Dyne Therapeutics initiated with a Buy at JonesTrading 01/07/21 Piper Sandler Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper 10/12/20 Jefferies Dyne Therapeutics initiated with a Buy at Jefferies 10/12/20 JPMorgan Dyne Therapeutics initiated with an Overweight at JPMorgan BIIB Biogen $266.84 / -3.2 (-1.19%) 02/17/21 Cantor Fitzgerald Biogen price target lowered to $268 from $278 at Cantor Fitzgerald 02/08/21 Citi Expert sees Biogen aducanumab approval 50/50 at best, says Citi 02/04/21 SVB Leerink Biogen price target lowered to $380 from $430 at SVB Leerink 02/04/21 Credit Suisse Biogen price target lowered to $338 from $350 at Credit Suisse DYN BIIB DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 11/05/20 Dyne Therapeutics reports Q3 EPS ($2.01), consensus (87c) BIIB Biogen $266.84 / -3.2 (-1.19%) 02/03/21 Biogen sees FY21 adjusted EPS $17.00-$18.50, consensus $24.67 02/03/21 Biogen reports Q4 adjusted EPS $4.58, consensus $4.87 02/02/21 Notable companies reporting before tomorrow's open 02/02/21 Notable companies reporting before tomorrow's open 21 Jan 17 Sep BIIB BIIB Biogen $266.84 / -3.2 (-1.19%) 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says DYN BIIB DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 01/21/21 Fly Intel: Wall Street's top stories for Thursday 01/21/21 Fly Intel: Wall Street's top stories at midday 09/28/20 Fly Intel: After-Hours Movers 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever BIIB Biogen $266.84 / -3.2 (-1.19%) 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday 02/03/21 Fly Intel: Pre-market Movers 01/29/21 Fly Intel: Wall Street's top stories for Friday 03/08/21 Biopharmaceuticals 06/07/21 PDUFA Date for Aducanumab BIIB BIIB Biogen $266.84 / -3.2 (-1.19%) 09/15/20 Alexion strength attributed to takeover speculation BIIB BIIB Biogen $266.84 / -3.2 (-1.19%) 01/29/21 Early notable gainers among liquid option names on January 29th 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th
Downgrade	Regency Centers downgraded to Hold from Buy at Argus » 07:29 03/04/21 03/04 07:29 03/04/21 07:29 REG Regency Centers $56.67 / +2.525 (+4.66%) Argus analyst Angus… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options REG Regency Centers $56.67 / +2.525 (+4.66%) 03/02/21 PS Business Parks appoints Dan Chandler as CEO 03/02/21 Regency Centers chief investment officer Mac Chandler to resign 01/27/21 Regency Centers issues TCFD Climate Change Risk Report 01/19/21 Regency Centers sold five shopping centers in Q4 for $77.8M REG Regency Centers $56.67 / +2.525 (+4.66%) 07:27 Today Argus Regency Centers downgraded to Hold from Buy at Argus 01/25/21 Compass Point Regency Centers upgraded to Buy from Neutral at Compass Point 12/30/20 Truist Regency Centers price target raised to $50 from $45 at Truist 08/19/20 Fly Intel: Top five analyst downgrades REG Regency Centers $56.67 / +2.525 (+4.66%) 02/11/21 Regency Centers sees FY21 FFO $2.96-$3.14, consensus $3.31 02/11/21 Regency Centers reports Q4 FFO 76c, consensus 72c 11/05/20 Regency Centers reports Q3 EPS 7c, consensus 21c REG Regency Centers $56.67 / +2.525 (+4.66%) 12/29/20 Early notable gainers among liquid option names on December 29th
Initiation	Open Lending initiated with an Outperform at William Blair » 07:29 03/04/21 03/04 07:29 03/04/21 07:29 LPRO Open Lending $38.72 / -1.3 (-3.25%) William Blair analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate Events Options LPRO Open Lending $38.72 / -1.3 (-3.25%) 01/12/21 Open Lending signs Royal Credit Union to Lenders Protection Program 12/16/20 Open Lending signs Members 1st Federal Credit Union to lenders protection 09/14/20 Open Lending signs Sound Credit Union to Lenders Protection Program LPRO Open Lending $38.72 / -1.3 (-3.25%) 02/10/21 Needham Open Lending initiated with a Buy at Needham 01/20/21 DA Davidson Open Lending price target raised to $45 from $31 at DA Davidson 01/04/21 Deutsche Bank Open Lending named 'Catalyst Call: Buy Idea' at Deutsche Bank 01/04/21 Stephens Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens 10 Dec 03/09/21 Open Lending - LPRO LPRO Open Lending $38.72 / -1.3 (-3.25%) 10/07/20 Five new option listings on October 7th
Hot Stocks	Hookipa Pharma announces publication on alternating 2-vector cancer therapeutics » 07:29 03/04/21 03/04 07:29 03/04/21 07:29 HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) HOOKIPA Pharma announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) 12/07/20 Hookipa Pharma reports 'positive' interim Phase 1 data on HB-201 11/30/20 Hookipa Pharma announces Phase 2 interim safety, efficacy results for HB-101 10/29/20 Hookipa Pharma doses first patient in Phase 1/2 trial for HB-202/HB-201 therapy 10/19/20 Hookipa Pharma appoints Jean-Charles Soria to board of directors HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) 11/30/20 JMP Securities Hookipa Pharma price target raised to $25 from $19 at JMP Securities 11/03/20 Fly Intel: Top five analyst initiations 11/03/20 Truist Hookipa Pharma initiated with a Buy at Truist 11/03/20 Truist Hookipa Pharma initiated with a Buy at Truist HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) 11/12/20 Hookipa Pharma reports Q3 EPS (53c), consensus (43c) 09 Dec HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) 12/08/20 Fly Intel: After-Hours Movers 03/15/21 Hookipa Pharma - HOOK

Events

Earnings calls, analyst events, roadshows and more

WVE
Today at 08:00

Wave Life Sciences - WVE Conference Calls
FULC
Today at 08:00

Fulcrum Therapeutics - FULC Conference Calls
HCM
Today at 08:00

Hutchison China MediTech - HCM Conference Calls
BALY
Today at 08:00

Bally's - BALY Conference Calls
ATC
Today at 08:00

Atotech - ATC Conference Calls
Today at 08:00

Consumer Data Analytics Industry Meetings
Today at 08:30

Initial Jobless Claims Level: Week 2/27/2021 Government Event
Today at 08:30

Initial Jobless Claims Change: Week 2/27/2021 Government Event
Today at 08:30

Jobless Claims: 4-Week Moving Average: Week 2/27/2021 Government Event
Today at 08:30

Productivity & Costs: Non-farm Poductivity Annual Rate: Q4(r):2020 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	SWTX X SWTX SpringsWorks Therapeutics Block Trade Managers: Morgan Stanley Priced at: $84.00 1.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRT X VRT Vertiv Holdings Block Trade Managers: JPMorgan Priced at: $20.70 17.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan Priced at: $120.00 2.08M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYNH X SYNH Syneos Health Secondary Managers: Goldman Sachs Priced at: $74.95 7M Shares EAF X EAF GrafTech Spot Secondary Managers: Morgan Stanley Priced at: $11.88 30M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FRC X FRC First Republic Spot Secondary Managers: BofA, JPMorgan & Morgan Stanley Priced at: $166.50 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HLNE X HLNE Hamilton Lane Spot Secondary Managers: JPMorgan Priced at: $88.25 1.45M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial JELD X JELD Jeld-Wen Spot Secondary Managers: Goldman Sachs Priced at: $29.25 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RCL X RCL Royal Caribbean Spot Secondary Managers: Morgan Stanley Priced at: $91.00 16.938M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SITC X SITC Site Centers Spot Secondary Managers: Morgan Stanley & Wells Fargo Priced at: $13.20 15M Shares WSC X WSC WillScot Mobile Mini Spot Secondary Managers: Morgan Stanley Priced at: $27.20 12.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	OSCR X OSCR Oscar Health IPO Managers: Goldman Sachs, Morgan Stanley & Allen & Co., Wells Fargo, Credit Suisse, BofA, Cowen, LION, Ramirez, SIEB Priced at: $39.00 31M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASLN X ASLN Aslan Pharmaceuticals Secondary Managers: Jefferies & Piper Sandler Priced at: $4.00 15M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDLX X CDLX Cardlytics Secondary Managers: BofA, JPMorgan, Wells Fargo & Raymond James Priced at: $130.00 3.85M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HSKA X HSKA Heska Secondary Managers: JPMorgan & Piper Sandler Priced at: $186.00 941K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INDT X INDT Indus Realty Trust Secondary Managers: Morgan Stanley, Citi & Baird, BTIG, JMP Securities, JPMorgan Priced at: $60.00 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MORF X MORF Morphic Secondary Managers: Jefferies, Cowen, BMO Capital & RBC Capital Priced at: $70.00 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ICAD X ICAD iCAD Spot Secondary Managers: Guggenheim Priced at: $18.00 1.222M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MGY X MGY Magnolia Oil & Gas Spot Secondary Managers: Credit Suisse & Citi Priced at: $10.50 17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.55 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PLXP X PLXP PLx Pharma Spot Secondary Managers: Raymond James & Oppenheimer Priced at: $8.00 7.88M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RDHL X RDHL RedHill Biopharma Spot Secondary Managers: H.C. Wainwright Priced at: $8.00 4.375M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SSYS X SSYS Stratasys Spot Secondary Managers: JPMorgan & Stifel Priced at: $29.00 6.897M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	INNV X INNV InnovAge IPO Managers: JPMorgan, Barclays, Goldman Sachs & Citi, Baird, William Blair, Piper Sandler, Capital One, Loop Capital, SIEB, Roberts & Ryans Priced at: $21.00 16.667M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial COHU X COHU Cohu Secondary Managers: Citi, Goldman Sachs & Stifel, B. Riley Securities, Craig-Hallum, DA Davidson Priced at: $41.00 4.95M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DGII X DGII Digi International Secondary Managers: Piper Sandler Priced at: $19.50 3.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SLQT X SLQT SelectQuote Secondary Managers: Credit Suisse, Morgan Stanley, Goldman Sachs, RBC Capital, Barclays, Citi, Evercore ISI & Jefferies, Cantor Fitzgerald, Keefe Bruyette, Piper Sandler, Drexel Hamilton Priced at: $27.50 10.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VICI X VICI VICI Properties Secondary Managers: Morgan Stanley, BofA, Citi & Deutsche Bank Priced at: $29.00 60M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DX X DX Dynex Capital Spot Secondary Managers: JPMorgan & JMP Securities Priced at: $18.35 3.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LASR X LASR nLight Spot Secondary Managers: Stifel & Raymond James Priced at: $34.00 2.206M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	EYE X EYE National Vision Block Trade Managers: JPMorgan $46.50-47.00 3.9M Shares AMRK X AMRK A-Mark Precious Metals Secondary Managers: DA Davidson & Roth Capital, CIBC $27.97 2.5M Shares FVRR X FVRR Fiverr Secondary Managers: JPMorgan, Goldman Sachs, Morgan Stanley $279.44 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RADA X RADA Rada Electronic Spot Secondary Managers: Jefferies, Baird & Canaccord, AGPR $11.50-11.75 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial STX X STX Seagate Spot Secondary Managers: JPMorgan $75.94 4.65M Shares
Thurs	NRIX X NRIX Nurix Therapeutics Secondary Managers: JPMorgan, Piper Sandler & Stifel, RBC Capital, Needham $35.91 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

View All Syndicate Announcements »

JPMorgan cuts Nikola target but sees 'generally positive' news flow in 2021

TODAY'S FREE FLY STORIES

Get Full Fly Access